Switching from Wegovy to Mounjaro is a common, prescriber-managed change — usually made because weight loss has plateaued, side effects haven't settled, or trial evidence for tirzepatide's stronger average results is appealing. The key thing to understand upfront: Mounjaro and Wegovy contain different active ingredients, so you don't carry your dose across. You restart Mounjaro at a low dose and titrate up — and no, that doesn't undo your progress.
Why people switch this way
- Plateaued results — after months on Wegovy's top dose, some people's weight loss stalls. Tirzepatide's dual-hormone action (GLP-1 + GIP) offers a genuinely different mechanism, and trials show greater average weight loss
- Side effects — tolerance is individual; some people who struggle on semaglutide feel noticeably better on tirzepatide (and vice versa)
- Headroom — Mounjaro's ladder runs to higher effect levels, which matters if you responded well to Wegovy but have significant weight still to lose
Why you can't transfer your dose
Semaglutide and tirzepatide milligrams aren't equivalent — Wegovy 2.4 mg has no "matching" Mounjaro dose. Starting tirzepatide high without building tolerance to it invites exactly the side effects titration exists to prevent. So switchers start at Mounjaro's lowest dose (2.5 mg) and step up on the standard schedule, with the prescriber adjusting pace to how you respond. It feels like a step backwards on paper; in practice most people who've tolerated a GLP-1 before move through the early doses comfortably.
How the switch works in practice
- Prescriber review — your history, current dose, response and side effects are assessed; the switch is confirmed as appropriate (or a better alternative suggested)
- Take your final Wegovy dose on your normal injection day
- Start Mounjaro about one week later, on the same weekly slot, at 2.5 mg — a washout period beyond this isn't usually needed, though your prescriber sets the exact plan
- Titrate on review — typically four weeks minimum per step, moving up only when you're tolerating well
What the first month feels like
Expect a transition period. At the starting dose, appetite suppression may feel weaker than your old Wegovy top dose — hunger can partially return for a few weeks. This is normal, temporary, and not a sign the switch failed. Lean on the habits you've built: protein-first meals, planned portions, regular movement. Mild digestive side effects can also reappear as your body meets a new molecule; the management playbook is the same as when you first started (smaller, slower, plainer meals and steady hydration).
Will I regain weight during the transition?
Some people see weight hold steady or tick up slightly during the low-dose weeks; most don't see meaningful change, and the trajectory resumes as the dose builds. Your progress isn't stored in the medicine — it's in your reduced weight itself and the habits you keep. Protect the habits and the transition is a blip, not a setback.
Switching the other way?
The same logic applies in reverse — Mounjaro to Wegovy switchers also restart at the new medicine's lowest dose. Reasons differ (cardiovascular licence, tolerability, availability), but the mechanics are identical. Read our Mounjaro vs Wegovy comparison for how the two differ.
Frequently asked questions
Do I have to start Mounjaro at 2.5mg if I was on high-dose Wegovy?
Yes — the active ingredients aren't interchangeable, and 2.5 mg is where tirzepatide tolerance is built. Your prescriber controls how quickly you move up from there.
Will I lose my progress switching medicines?
No. Weight already lost is yours, and the habits you've built continue working. A few lower-appetite-suppression weeks during titration are normal and temporary.
How long between the last Wegovy dose and first Mounjaro dose?
Typically about one week — your next normal injection day. Your prescriber confirms the exact timing for your situation.
Will Mounjaro definitely work better for me than Wegovy?
Not guaranteed — trial averages favour tirzepatide, but individual response varies. If Wegovy stopped working for you, a different mechanism is a reasonable next step, monitored over the first few months.
References
- Jain AB, et al. Switching between GLP-1 receptor agonists in clinical practice: expert consensus and practical guidance. Int J Clin Pract. 2021.
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.
- Mounjaro KwikPen — Summary of Product Characteristics. medicines.org.uk.
- Wegovy — Summary of Product Characteristics. medicines.org.uk.